Last reviewed · How we verify
NK520
At a glance
| Generic name | NK520 |
|---|---|
| Also known as | genetic modified NK cell |
| Sponsor | Base Therapeutics (Shanghai) Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy of NK520 to Treat Relapsed/Refractory Acute Myeloid Leukemia (EARLY_PHASE1)
- Safety and Efficacy of NK520 to Treat Pediatric Relapsed/Refractory Acute Myeloid Leukemia (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NK520 CI brief — competitive landscape report
- NK520 updates RSS · CI watch RSS
- Base Therapeutics (Shanghai) Co., Ltd. portfolio CI